BioNexus Gene Lab Corp Common stock (BGLC) — Financial Flexibility Index
BioNexus Gene Lab Corp Common stock (BGLC) has a Financial Flexibility Index of -1.53x as of September 2025. Free cash flow of $-1.23 Million (operating CF $-1.23 Million minus capex $5.49K) represents -2% of total liabilities ($804.97K). Check BioNexus Gene Lab Corp Common stock cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BioNexus Gene Lab Corp Common stock Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for BioNexus Gene Lab Corp Common stock across 9 annual periods. For the full cash flow conversion analysis, see BGLC operating cash flow.
Annual Financial Flexibility Index for BioNexus Gene Lab Corp Common stock (2016–2024)
Year-by-year free cash flow to debt coverage for BioNexus Gene Lab Corp Common stock. Explore BGLC debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.95x | $-2.01 Million | $-2.23 Million | $2.11 Million | ▼ -2.8% |
| 2023 | -0.93x | $-1.61 Million | $-1.76 Million | $1.74 Million | ▼ -420.9% |
| 2022 | 0.29x | $598.20K | $544.03K | $2.08 Million | ▲ +5501.6% |
| 2021 | 0.01x | $12.32K | $9.16K | $2.39 Million | ▼ -98.2% |
| 2020 | 0.28x | $974.30K | $552.68K | $3.45 Million | ▲ +115.0% |
| 2019 | -1.88x | $-204.46K | $-217.27K | $108.87K | ▼ -4.4% |
| 2018 | -1.80x | $-234.46K | $-274.08K | $130.31K | ▼ -415.4% |
| 2017 | 0.57x | $672.04K | $357.22K | $1.18 Million | ▲ +191.3% |
| 2016 | -0.62x | $-835.00 | $-835.00 | $1.34K | — |